Major Lipids, Apolipoproteins, and Risk of Vascular Disease

By G. Moneta. 2010

1,651 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/fc3883bb12d29b79dd1b936936ba79983931bbe4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Massimo F. Piepoli
2. S. Thompson
3. Stephen Burgess
4. I. Graham
5. Børge G. Nordestgaard
6. George Davey Smith
7. Michael Holmes
8. Bart Staels

In Endocrinology, Diabetes and Metabolism

1. Børge G. Nordestgaard
2. I. Graham
3. Massimo F. Piepoli
4. A. Varbo
5. A. Tybjærg-Hansen
6. S. Grundy
7. S. Thompson
8. Stephen Burgess

In Surgery

1. I. Graham
2. Børge G. Nordestgaard
3. Massimo F. Piepoli
4. A. Varbo
5. A. Tybjærg-Hansen
6. S. Thompson
7. Stephen Burgess
8. J. Bowden

Citations in the corpus

• Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. (2012, background): “74) risk reduction per mmol/l lower non-HDL cholesterol (and directly measured LDL-C) observed in a large meta-analysis (39) of prospective cohort studies (p for difference 7.”
• European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “Total risk estimation using multiple risk factors (such as SCORE) is recommended for asymptomatic adults without evidence of CVD.”
• Association Between Dietary Factors and Mortality From Heart Disease, Stroke, and Type 2 Diabetes in the United States (2017, neutral): “2) High-school N deaths 19 (12, 24) 18 (11, 23) 102 (63, 124) 64 (37, 78) 304 (182, 403) 238 (127, 309) 790 (463, 1072) 558 (319, 761) 1093 (644, 1521) 847 (482, 1185) 1871 (1180, 2550) 3699 (2400, 4857) 9565 (7941, 11144) % OSTK 61 (38.”
• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013, background): “Targeting other aspects of lipid metabolism, such as high-density lipoprotein cholesterol (HDL-C), triglycerides, and lipoprotein (a) [Lp(a)], as well as lowering LDL-C further, offers the prospect of additional cardiovascular risk reduction.(3,4)”
• Macrophage phenotypes in atherosclerosis (2014, background): “Epidemiological studies have consistently demonstrated an inverse correlation between plasma high density lipoprotein cholesterol (HDL-C) and the risk of coronary artery disease and its thrombotic complications (136, 137).”